



NEOVASC CORPORATE FACT SHEET

About Neovasc

Neovasc Inc. (TSXV: NVC) is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves.

Neovasc Reducer™ Receives CE Mark for Treatment of Refractory Angina

The Neovasc Reducer, an implantable device for the treatment of refractory angina, has recently received CE mark designation allowing it to be sold in the European Union. Refractory angina occurs when inadequate blood flow to the heart cannot be managed through conventional therapy. The disease causes severe heart pain and significant disability, affecting an estimated two million patients in Europe and the US. Neovasc's Reducer works by modulating the outflow of blood from certain veins in the heart, forcing oxygenated blood deeper into the heart muscle where it reaches oxygen-starved ischemic tissue and reduces angina pain. Neovasc plans to initiate targeted commercial release of the product through a European patient registry beginning in early 2012.

In an initial three-year trial, the Reducer demonstrated excellent safety and efficacy. Neovasc is currently enrolling 124 patients in the COSIRA study, a double-blind, randomized, sham-controlled multicenter trial intended to further demonstrate the Reducer's safety and efficacy in refractory angina patients. Completion of patient enrollment is targeted for 2012, and US clinical trials are planned following completion of the study. The Reducer was featured in a "live case" broadcast at TCT 2010. A panel of leading interventional cardiologists expressed enthusiasm for the procedure's simplicity and the Reducer's potential to help refractory angina patients. At the EuroPCR 2011 cardiovascular conference, positive six-month follow-up data for the "live case" patient showed a marked improvement in angina symptoms. Similar positive results have been observed in other patients who have been implanted with the Reducer under special access regulatory approvals.

Tiara™ Program

Neovasc is currently developing its Tiara technology, a novel solution to treat mitral valve regurgitation (MR), a serious and poorly served condition that requires development of highly specialized transcatheter devices to address the complex mitral anatomy. About four million US patients are estimated to have MR, yet many are too ill for conventional surgery. With its strong background in vascular device and tissue heart valve development and manufacture, Neovasc believes it is well positioned to develop new therapies for MR. While the Tiara project is early stage, development work to date has yielded promising results and the first implantation in humans is targeted around the end of 2012.

Tissue Products & Services

Neovasc develops, manufactures and markets pericardial tissue-based devices based on its proprietary biological tissue technology, PeriPatch™, a flexible, biocompatible collagen tissue patch. PeriPatch has a 20-year history of successful use in general and vascular surgery and cardiac applications, including in the fabrication of conventional and transcatheter heart valves. Neovasc primarily sells PeriPatch tissue to industry partners and customers who then use the material as a component in their own medical products. Neovasc is a leading provider of tissue for transcatheter aortic and mitral heart valve programs. It also provides specialized manufacturing and development services related to tissue-based implantable products, including transcatheter valves. Neovasc's tissue business is currently operating at cash flow positive.

Expected 2012 Milestones

- Complete COSIRA enrollment
- Initiate targeted European launch of Reducer through REDUCE-1 registry
- Conduct first implantation of Tiara mitral device in humans
- Continue to grow biological tissue business revenues, with upside potential as customers' new products advance to commercialization.

Financial Snapshot

(At 12/31/11, unless noted)

TSXV: NVC

Market Cap: ~\$60M

Cash & Cash Equivalents: ~\$4M

2011 Revenue: ~\$5M+

Shares Outstanding: ~45.7M

Management

Alexei Marko, CEO & Director

Christopher Clark, CFO

Brian McPherson, COO

Prof. Shmuel Banai, MD, Medical Director

Contacts

Neovasc Inc.

604.270.4344

info@neovasc.com

www.neovasc.com

Media & US Investors

Barbara Lindheim or

Jennifer Anderson

GendeLLindheim BioCom Partners

212.584.2276

info@biocompartners.com